• Earlier this month, Bristol Myers Squibb announced a wide-ranging partnership with Anthropic to deploy Claude AI across R&D, clinical development, manufacturing, commercial, and corporate functions to help accelerate drug development and operational workflows.
• This move, combined with Bristol Myers Squibb’s separate AI-focused collaboration with Tempus AI on clinical trial design, signals a broad push to integrate advanced data and AI tools throughout the company’s development pipeline.
• We’ll now examine how Bristol Myers Squibb’s push to embed Claude AI across its operations could reshape the company’s existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 46 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Bristol-Myers Squibb Investment Narrative Recap

To own Bristol Myers Squibb, you need to believe its diversified pipeline and business development can offset looming patent cliffs and pricing pressure, even as consensus forecasts a multi‑year revenue and earnings decline. The new AI partnership with Anthropic, alongside Tempus AI, could modestly influence the key short term catalyst: execution on late‑stage oncology and immunology launches. The biggest risk remains how quickly revenue from Eliquis, Opdivo and other legacy products erodes.

The most relevant recent announcement here is BMS’s ASCO 2026 oncology data slate, including Phase 3 readouts for CELMoD assets like mezigdomide and early results for next generation CAR T and ADC programs. Together with AI‑enabled trial design, this cluster of oncology updates goes straight to the heart of the near term catalyst question: can new cancer medicines and label expansions scale quickly enough to reposition the story away from patent expiries?

Yet beneath this AI and oncology progress, investors still need to watch for intensifying patent and pricing headwinds that could...

Bristol-Myers Squibb’s narrative projects $40.1 billion revenue and $8.6 billion earnings by 2029. This requires a 6.2% yearly revenue decline and an earnings increase of about $1.3 billion from $7.3 billion today.

Uncover how Bristol-Myers Squibb's forecasts yield a $62.96 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Compared with the consensus view, the most optimistic analysts already expected earnings to climb toward about US$10.4 billion by 2029, so Claude and Tempus‑driven R&D improvements could either reinforce that upbeat margin story or expose how sensitive those forecasts are to real world trial outcomes and cost savings.

Explore 12 other fair value estimates on Bristol-Myers Squibb - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Bristol-Myers Squibb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bristol-Myers Squibb's overall financial health at a glance.

Contemplating Other Strategies?

Our top stock finds are flying under the radar-for now. Get in early:

• Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.